-
1.发明申请Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation 审中-公开PAR-2激活的作用及其在炎症调节中的应用公开(公告)号：US20110311553A1
公开(公告)日：2011-12-22
申请号：US13160758
申请日：2011-06-15
申请人： Tobias LITZENBURGER , Sandra MILLER , Catrin PRACHT , Rainer BOXHAMMER , Jeanne MAGRAM , Patricia GIBLIN , Daniel RAJOTTE
发明人： Tobias LITZENBURGER , Sandra MILLER , Catrin PRACHT , Rainer BOXHAMMER , Jeanne MAGRAM , Patricia GIBLIN , Daniel RAJOTTE
IPC分类号： A61K39/395 , A61P29/00 , A61P11/06 , A61P19/02 , A61P17/00 , A61P1/00 , C07K16/28 , A61P17/06
CPC分类号： C07K16/28 , A61K2039/505 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.
摘要翻译： 本发明涉及PAR-2受体扩增炎症反应的认识，因此PAR-2活化的作用者可用于调节炎症反应，从而赋予患者治疗益处。 本发明特别涉及使用PAR-2效应物治疗由炎症，癌症和损伤引起的炎症和伤害感受（疼痛）。 本发明特别涉及PAR-2活化的负效应物，更特别地涉及作为PAR-2活化的负效应物的抗PAR-2抗体。
-
2.发明授权Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL 有权抗CD38抗体和来那度胺或硼替佐米用于治疗多发性骨髓瘤和NHL公开(公告)号：US08877899B2
公开(公告)日：2014-11-04
申请号：US13825325
申请日：2011-09-26
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30 , A61K31/69 , A61K45/06 , A61K38/07 , A61K38/05 , A61K31/454 , A61K39/00
CPC分类号： C07K16/40 , A61K31/454 , A61K31/69 , A61K38/05 , A61K38/07 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2896 , C07K16/3061 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , A61K2300/00
摘要： The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
摘要翻译： 本公开描述了抗CD38抗体和来那度胺的药物组合以及抗CD38抗体和硼替佐米的药物组合。
-
3.发明申请Anti-CD38 Antibody and Lenalidomide or Bortezomib for the Treatment of Multipe Myeloma and NHL 有权抗CD38抗体和来那度胺或硼替佐米用于治疗多发性骨髓瘤和NHL公开(公告)号：US20130302318A1
公开(公告)日：2013-11-14
申请号：US13825325
申请日：2011-09-26
IPC分类号： A61K39/395 , A61K31/69 , A61K38/07 , A61K31/454
CPC分类号： C07K16/40 , A61K31/454 , A61K31/69 , A61K38/05 , A61K38/07 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/28 , C07K16/2896 , C07K16/3061 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , A61K2300/00
摘要： The present disclosure describes a pharmaceutical combination of an anti-CD38 antibody and lenalidomide and a pharmaceutical combination of an anti-CD38 antibody and bortezomib.
摘要翻译： 本公开描述了抗CD38抗体和来那度胺的药物组合以及抗CD38抗体和硼替佐米的药物组合。
-
4.发明申请Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation 审中-公开PAR-2激活的作用及其在炎症调节中的应用公开(公告)号：US20100119506A1
公开(公告)日：2010-05-13
申请号：US12512251
申请日：2009-07-30
申请人： Tobias LITZENBURGER , Sandra MILLER , Catrin PRACHT , Rainer BOXHAMMER , Jeanne MAGRAM , Patricia GIBLIN , Daniel RAJOTTE
发明人： Tobias LITZENBURGER , Sandra MILLER , Catrin PRACHT , Rainer BOXHAMMER , Jeanne MAGRAM , Patricia GIBLIN , Daniel RAJOTTE
IPC分类号： A61K39/395 , C07K16/00 , A61P37/06
CPC分类号： C07K16/28 , A61K2039/505 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The present invention relates to the recognition that PAR-2 receptors amplify the inflammatory response and that effectors of PAR-2 activation can thus be used to modulate the inflammatory response and thereby impart therapeutic benefit to patients. The invention is particularly directed to the use of PAR-2 effectors in the treatment of inflammation and nociception (pain) caused by inflammation, cancer and injury. The invention is particularly directed to negative effectors of PAR-2 activation, and more particularly to anti-PAR-2 antibodies that are negative effectors of PAR-2 activation.
摘要翻译： 本发明涉及PAR-2受体扩增炎症反应的认识，因此PAR-2活化的作用者可用于调节炎症反应，从而赋予患者治疗益处。 本发明特别涉及使用PAR-2效应物治疗由炎症，癌症和损伤引起的炎症和伤害感受（疼痛）。 本发明特别涉及PAR-2活化的负效应物，更特别地涉及作为PAR-2活化的负效应物的抗PAR-2抗体。
-
-
-
搜索结果
4 条记录 (耗时 0.019 秒)
